Compare ADMA Biologics Inc (ADMA) vs Duolingo Inc (DUOL) Price & Performance

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

DUOL trades at $130.9, up 6.79% in 24 hours, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates at $0.66 versus $0.604 expected, driven by 23% daily active user growth. However, a lower Q3 revenue forecast has tempered optimism. Fundamentals show robust revenue growth to $1.04B in 2025 and a net income margin of 35.87%, though valuation multiples like P/E of 15.47 and P/S of 5.6 suggest premium pricing.

Outlook is mixed: strong user engagement and profitability support upside, but monetization concerns and competitive pressures pose risks. Analysts are cautious with a $121 consensus price target below current levels, highlighting execution challenges in converting growth to sustained revenue.